Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy company developing drug-delivery platforms for cancer and diabetes. The company has no approved products and generates no product revenue, operating entirely on equity financing while advancing its pipeline through preclinical and clinical research. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene via a lipid nanoparticle delivery system and is being studied in non-small cell lung cancer, including in combination with sotorasib in KRAS-G12C mutant NSCLC. Genprex also holds exclusive licenses from the University of Pittsburgh for a gene therapy approach targeting Type 1 and Type 2 diabetes, using MafB promoter-driven expression of Pdx1 and MafA transcription factors delivered via AAV construct. Preclinical mouse and non-human primate studies have been conducted. The company relies on sponsored research agreements and third-party contract manufacturers for production. As of the 10-K filed 2026-03-30, Genprex remained a pre-revenue, smaller reporting company listed on The Nasdaq Capital Market.

Revenue model

Genprex has no product revenue. Operations are funded through equity issuances. The company incurs research and development expenses and general and administrative costs, with no commercial product sales as of the 10-K filed 2026-03-30.

Products and services

REQORSA (quaratusugene ozeplasmid): TUSC2 gene therapy candidate for non-small cell lung cancer, studied in combination with KRAS inhibitor sotorasib in KRAS-G12C mutant NSCLC. Diabetes gene therapy program: AAV-delivered MafB promoter driving Pdx1 and MafA transcription factors for Type 1 and Type 2 diabetes, licensed exclusively from the University of Pittsburgh under a February 2025 agreement.

Customers and end markets

End markets are oncology (non-small cell lung cancer) and endocrinology (Type 1 and Type 2 diabetes). No commercial customers exist as of the 10-K filed 2026-03-30. Potential future customers would include hospitals, oncology clinics, and third-party payors including Medicare and Medicaid.

Value-chain role

Genprex is a drug developer that licenses IP from academic institutions, sponsors preclinical and clinical research through collaborators such as MD Anderson Cancer Center and the University of Pittsburgh, and relies on third-party contract manufacturers for product candidate production. It holds no internal manufacturing capacity.

Geographic exposure

Incorporated and operating in the United States, listed on The Nasdaq Capital Market. Subject to U.S. FDA regulatory oversight and, where applicable, international regulations including the UK Bribery Act and EU anti-corruption laws.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Black Diamond Therapeutics Inc Harvard Apparatus Regenerative Technology Inc Cardiff Oncology Inc Cyteir Therapeutics, Inc. Equillium Inc iBio Inc Passage Bio Inc TCR2 THERAPEUTICS INC.